Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activated T cells for the induction of immune tolerance 1,2 . Tumour cells frequently overexpress the ligand for PD-1, programmed cell death ligand 1 (PD-L1), facilitating their escape from the immune system 3,4 . Monoclonal antibodies that block the interaction between PD-1 and PD-L1, by binding to either the ligand or receptor, have shown notable clinical efficacy in patients with a variety of cancers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma 5-9 .
abundant population of cells that expressed both the macrophage marker CD68 and PD-1 ( Fig. 1b and Extended Data Fig. 2a (no primary control)), further confirming the expression of PD-1 on TAMs.
TAMs are often thought to polarize towards an inflammatory 'M1' or pro-tumour 'M2' state, depending on their environmental stimuli 18 . Flow cytometry analysis showed that almost all PD-1 + TAMs expressed an M2-like surface profile ( Fig. 1c ), whereas PD-1 − TAMs showed a trend towards the expression of an M1-like profile (Extended Data Fig. 2b ). Further analysis of mouse CT26 tumours in syngeneic hosts revealed that this PD-1 + TAM population is not static; it begins to emerge circa 2 weeks after engraftment, and increases over time (Fig. 1d, left) . We found that PD-1 expression correlated strongly with time after engraftment (Fig. 1d, right) , as well as with tumour volume (Extended Data Fig. 2d ).
Given these observations in mice, we wondered whether human macrophages similarly express PD-1 in the primary tumour setting. Upon profiling the TAMs in human colorectal cancer samples, we found high but variable PD-1 expression on human TAMs. Notably, we also found that, similar to what was observed in mice, the M2 population expressed significantly more PD-1 than the M1 population (Fig. 1e) , and the PD-1 − population had a predominantly M1 phenotype (Extended Data Fig. 2c ). Furthermore, the frequency of PD-1 + TAMs increased with disease stage, but only within the M2 subset ( Fig. 1f, g) . These data from primary clinical samples suggest that, similar to what we observed in mouse tumours, M2 PD-1 + TAMs probably accumulate over time in the tumour microenvironment in human cancer.
We hypothesized that this time-dependent increase in PD-1 + TAMs in both mice and humans could be mainly attributed to bonemarrow-derived macrophages homing to the inflammatory tumour microenvironment, rather than from yolk-sac-derived tissue-resident macrophages differentiating into PD-1 + cells. To investigate the origin of these cells, we performed a bone marrow transplantation experiment. Donor bone marrow from RFP + C57BL/6 mice was engrafted into irradiated host GFP + C57BL/6 mice. After 6 weeks, we verified engraftment by assessing donor chimaerism in the myeloid (CD11b + ), granulocyte (Gr1 high ), T cell (TCRβ + ) and B cell (CD19 + ) compartments (Extended Data Fig. 2e ). We then engrafted the bonemarrow-transplanted mice with MC38 tumours, a colon cancer model syngeneic to the C57BL/6 background. After 3 weeks, significantly higher fractions of PD-1 + TAMs and PD-1 + tumour-infiltrating lymphocytes (TILs) were derived from donor RFP + bone marrow ( Fig. 2a ). This suggests that the majority of PD-1 + TAMs and TILs originate from circulating leukocytes, rather than from resident immune cells.
We further characterized the phenotype of PD-1 + TAMs by a variety of microscopy-and flow-cytometry-based techniques. Giemsa Letter reSeArCH staining of FACS-sorted TAMs from dissociated CT26 tumours showed marked differences in their morphology. PD-1 + TAMs appeared large and 'foamy' (filled with vacuoles and/or lipids) in contrast to PD-1 − TAMs, which were smaller and more monocytic in appearance (Fig. 2b ). Electron microscopy of these PD-1 + TAMs confirmed that this foamy appearance was in part due to the accumulation of abundant, uncleared phagocytic material and lysosomes within the cytoplasm (Fig. 2c ).
FACS analysis of typical TAM markers showed that PD-1 + and PD-1 − TAMs from CT26 tumours expressed equivalent levels of CD11b and F4/80, but that PD-1 + TAMs express more of the M2-associated scavenger receptor CD206, less MHC class II, and more CD11c (Fig. 2d, e ). Notably, almost all PD-1 + TAMs and a high fraction of PD-1 − TAMs expressed CD4, a marker typically associated with T cells, but also known to mark a subset of myeloid cells, including macrophages [19] [20] [21] (Fig. 2d, f) . We confirmed coexpression of CD68 and CD4 on FACS-sorted TAMs by immunofluorescence microscopy ( Fig. 2g and Extended Data Fig. 2a (no primary control)). Levels of CD4 were also higher on PD-1 + human TAMs in both the M1 and M2 subsets compared to their PD-1 − counterparts ( Fig. 2f ).
Beyond its role as a marker of a distinct macrophage subset, we hypothesized that PD-1 expression could affect TAM phagocytosis by limiting the effector functions of activated TAMs, analogous to the role it plays in the inhibition of stimulated T cells. To test this hypothesis, we FACS-sorted PD-1 + and PD-1 − TAMs from CT26 tumours, and conducted an ex vivo phagocytosis assay with GFP + Staphylococcus aureus bioparticles. PD-1 + TAMs showed a reduced degree of phagocytosis of S. aureus bioparticles compared to the PD-1 − TAMs (Extended Data Fig. 3a-c ), suggesting that the PD-1 + TAMs have a reduced capacity for phagocytosis. To further investigate this inhibition in vivo, we used immunocompromised BALB/c Rag2 −/− /Il2rg −/− (also known as Rag2 −/− γc −/− ) mice, which lack an adaptive immune system, to study TAM phagocytosis of fluorescent cancer cells. Similar to immunocompetent mice, BALB/c Rag2 −/− γc −/− mice showed PD-1 expression specifically on TAMs (Extended Data Fig. 4a ), as well as a correlation between PD-1 expression and tumour volume (Extended Data Fig. 4b ).
We generated two sublines of YFP + CT26 cells, one with constitutive overexpression of PD-L1 (PD-L1 overexpressing) and the other deficient in PD-L1 (PD-L1 knockout). First we engrafted PD-L1 overexpressing tumours, which should constitutively agonize PD-1 signalling, in BALB/c Rag2 −/− γc −/− mice. We then assessed total phagocytosis levels in the tumour by analysing the percentage of TAMs that were also YFP + (Extended Data Fig. 5a (representative gates)). In accordance with our hypothesis with regards to an inhibitory role for PD-1 on TAMs, we found that the frequency of PD-1 expression significantly and inversely correlated with total in vivo phagocytosis levels ( Fig. 3a ). Furthermore, FACS analysis of PD-1 − versus PD-1 + TAMs showed that PD-1 − TAMs phagocytosed significantly more CT26 tumour cells in vivo than PD-1 + TAMs (Fig. 3b ).
To determine whether this decrease in phagocytosis could be reversed with the removal of the ligand, PD-L1, we engrafted PD-L1overexpressing and PD-L1-knockout tumours in BALB/c Rag2 −/− γc −/− mice. After 3 weeks, tumours in the PD-L1-knockout group were significantly smaller than tumours with PD-L1 overexpression ( Fig. 3c ), supporting the hypothesis that PD-1-PD-L1 antagonism enhances myeloid anti-tumour efficacy. Upon analysing the phagocytic capacity of both PD-1 − and PD-1 + TAMs, we found that, as expected, removal of PD-L1 had no effect on phagocytosis by PD-1 − macrophages (Extended Data Fig. 5b ). By contrast, PD-L1 knockout significantly increased phagocytosis by PD-1 + macrophages ( Fig. 3d ). PD-L1 knockout did not directly affect the percentage of PD-1 + TAMs (Extended Data Fig. 5c ).
The decrease in tumour burden and increase in PD-1 + TAM phagocytosis upon PD-L1 removal suggests that the PD-1-PD-L1 pathway specifically inhibits TAM function. To demonstrate that this enhancement of TAM anti-tumour immunity could be modulated by therapeutic blockade of the PD-1-PD-L1 interaction, we treated immunocompromised mice with either a PD-1 blocker (anti-mouse PD-1 antibody) or a PD-L1 blocker (HAC, an engineered, small protein with human PD-L1-blocking activity) 22 . Previous reports have suggested that mouse and human tumour cells can acquire expression of the PD-1 receptor to drive tumour growth 23 , so to eliminate the possibility that an anti-mouse PD-1 antibody could elicit an anti-tumour effect by binding to PD-1 on the cancer cells rather than on the macrophages, we used a human colon cancer xenograft model, DLD-1, which could not express mouse PD-1. We engrafted DLD cells constitutively expressing PD-L1 and GFP-luciferase (GFP-luc) into NOD.Cg-Prkdc SCID Il2rg tm1Wjl /SzJ (NSG) mice, an immunocompromised strain that shows improved engraftment of human cells compared to Rag2 −/− γc −/− mice. These cells should continually agonize mouse TAM PD-1 signalling 24 , an effect that should be blocked by administration of the anti-mouse PD-1 antibody, or the anti-human PD-L1 small protein, HAC. As expected, NSG mice engrafted with DLD-tg(PD-L1)-GFP-luc + tumours showed tumour-specific expression of PD-1 on TAMs (Extended Data Fig. 4c ), and shared the previously observed correlation between PD-1 expression and tumour volume (Extended Data Fig. 4d ). Mice treated with either PD-1 blockade (anti-mouse PD-1 antibody) or PD-L1 blockade (HAC) had an equivalent and significant reduction in tumour growth ( Fig. 3e ). TAM depletion (See Methods for TAM depletion protocol, and Extended Data Fig. 6a , b for TAM depletion) abrogated the effects that HAC and anti-PD-1 treatment had on tumour size (Fig. 3f ). With Representative histograms are shown. e, Analysis of TAM markers in PD-1 − versus PD-1 + subsets from CT26 tumours shows that PD-1 + TAMs express more CD206 (left), less MHC II (middle) and more CD11c (right). n = 5, experiment conducted once. Paired one-tailed t-test. f, Mouse (left) and human (right) PD-1 + TAMs have higher expression of CD4 than PD-1 − TAMs. n = 10, three experimental repeats. Paired two-tailed t-test. g, Immunofluorescence images of FACS-sorted TAMs from CT26 tumours confirms that CD4 and CD68 are expressed together. n = 2, two experimental repeats. Representative images are shown; 20× magnification; scale bar, 20 μ m. Red, CD4; green, CD68; blue, Hoechst. Data are mean ± s.e.m.; * P < 0.05; * * P < 0.01; * * * P < 0.001; * * * * P < 0.0001; NS, not significant.
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these treatment experiments, we demonstrate that specific inhibition of the PD-1-PD-L1 axis in TAMs is responsible for the anti-tumour efficacy that we observed. This effect cannot be due to the Fc-mediated phagocytosis of PD-L1 + cancer cells 25 , as HAC lacks an Fc-domain 22 , and can therefore be attributed to the specific blockade of the PD-L1 pathway.
Given that patients in early clinical trials are already receiving anti-CD47 therapy, and that this therapeutic strategy will probably be combined with PD-1-PD-L1 blockade, we sought to determine how PD-1-PD-L1 therapies might interact with anti-CD47 in the context of macrophage-mediated immunotherapy. We carried out another treatment study using the same DLD xenograft in NSG mice, with four treatment groups (PBS, HAC, anti-CD47 and combined HAC and anti-CD47). Both HAC and anti-CD47 monotherapies were able to equivalently reduce tumour size, with tumours in the group treated with a combination of HAC and anti-CD47 showing a trend towards the greatest reduction ( Fig. 3g ). This enhancement in anti-tumour efficacy also had an effect on survival, with both HAC and anti-CD47 monotherapy groups living significantly longer than the PBS control ( Fig. 3h ). Combination therapy trended towards increasing survival more than either monotherapy ( Fig. 3h ).
Here we demonstrate that both mouse and human TAMs express high levels of PD-1, and that PD-1 increases with stage of disease. PD-1 expression on TAMs correlates with decreased phagocytosis, but PD-L1 removal increases PD-1 + TAM phagocytosis in vivo and decreases tumour burden, suggesting that TAM function can be rescued. PD-1 expression inhibits numerous immune cell subsets in the tumour microenvironment, including T cells, B cells 26 , natural killer cells 27 and dendritic cells 28 . We can now expand this to include macrophages, suggesting that PD-1 expression is a global mechanism for limiting immunity across the innate and adaptive immune system. Given that cancer patients now routinely receive anti-PD-1 or anti-PD-L1 therapies, the effects of PD-1 blockade on macrophages in human cancer should not be neglected, as they may help to find new disease indications or treatment combinations. As one example, anti-PD-1 agents have proven highly effective against Hodgkin's lymphoma, despite heterogeneous PD-1 expression on TILs 29 and frequently compromised surface expression of MHC class I on tumour cells 30 , potentially precluding a T-cellmediated mechanism for anti-tumour efficacy. This discordance could in part be explained by a macrophage-mediated anti-tumour effect in Hodgkin's lymphoma that is enabled by PD-1-PD-L1 blockade.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
MethOdS Statistics note. One-tailed P values were calculated whenever a hypothesis had been made before the experiment, and two-tailed P values were calculated when a hypothesis was not determined beforehand. Variance was similar between the groups that were compared statistically. No statistical methods were used to predetermine sample size. Cell lines. The mouse colon carcinoma cell lines CT26 and MC38, and the human colon carcinoma cell line DLD-1, were purchased from ATCC. CT26-tg(hPD-L1)-Δ (mPD-L1) and CT26-Δ (mPD-L1) cells (engineering strategy described previously 22 ) were infected with YFP-luciferase retrovirus to generate CT26tg(hPD-L1)-Δ (mPD-L1)-YFP-luc + and CT26-Δ (mPD-L1)-YFP-luc + cells. After 72 h, infected cells were expanded and FACS-sorted to generate uniformly YFP + populations. DLD-tg(hPD-L1)-GFP-luc + cells were generated by transducing DLD cells with a lentivirus for constitutive, EF1A-driven expression of hPD-L1, as well as a lentivirus for GFP-luciferase. All cells were cultured in a humidified, 5% CO 2 incubator at 37 °C, and grown in RPMI or DMEM with 10% fetal bovine serum (FBS) and 100 U ml −1 penicillin/streptomycin (Life Technologies). All cell lines were tested for mycoplasma contamination. Ex vivo pHrodo-green Staphylococcus aureus phagocytosis assay. 20,000 FACSsorted PD-1 − and PD-1 + TAMs were plated in an ultra-low attachment 96-well plate (Corning) for 15-20 min at 37 °C to allow them to rest after sorting. TAMs were then spun down at 1,200g, for 5 min, at 4 °C, and resuspended in 100 μ l pHrodo-green S. aureus bioparticles (ThermoFisher) as per the manufacturer's instruction. After a 2 h incubation at 37 °C, TAMs were spun down and restained with F4/80 in the same fluorescent channel as the cells had been sorted on, and the phagocytosis assay was subsequently analysed by flow cytometry. TAMs that were GFP high were considered to be phagocytosing. Protein expression and purification. High-affinity PD-1 protein (HAC) was produced as described previously 22 . Mice. BALB/c mice were purchased from Jackson Laboratory. BALB/c Rag2 −/− γc −/− , NOD.Cg-Prkdc SCID Il2rg tm1Wjl /SzJ (NSG), RFP + C57BL/6 and GFP + C57BL/6 mice were obtained from in-house breeding stocks. All experiments were carried out in accordance with guidelines set by the Stanford University Administrative Panel on Laboratory Animal Care, and with IRB approval. Investigators were not blinded for animal studies. FACS of mouse macrophages. Circulating blood samples were taken by cardiac puncture, and collected into blood collection tubes (Terumo) to prevent clotting. Blood cells were lysed in ACK lysis buffer (Invitrogen) for 10 min, filled with PBS to stop the reaction, and spun down for 5 min at 4 °C and 1,200 r.p.m. Samples were resuspended in FACS buffer (PBS with 2% FBS) for staining. Splenic samples were isolated by dissociating spleens over a 100-μ m filter, and then washing in FACS buffer. After spinning down for 5 min at 4 °C and 1,200 r.p.m., blood cells were lysed as above, and the finished splenic sample resuspended in FACS buffer. Tumours were resected from mice and mechanically dissociated with a straightedge razor and then digested with 5-10 ml HBSS containing Ca/Mg (Corning), 10 μ g ml −1 DNase I (Sigma Aldrich) and 25 μ g ml −1 Liberase (Roche) for 30 min at 37 °C, the solution was mixed by pipetting every 10 min. After dissociation, tumour suspensions were filtered through a 70-μ m filter, put on ice, washed with cold PBS, and spun down for 5 min at 4 °C and 1,200 r.p.m. Sample blood cells were lysed as above, and then the samples were resuspended in FACS buffer and blocked with 1 μ g rat serum IgG per 10 6 cells (Sigma Adrich) for 15 min before staining with the antibody panel. Antibody panels were constructed as listed below, with clones used listed in Supplementary Table 1 . Photomultiplier tube (PMT) voltages were set with fully stained samples, and compensations were performed with single-stained UltraComp eBeads (Affymetrix) or cells. For all channels, positive and negative cells were gated on the basis of Fluorescence Minus One controls (FMOs), and PD-1 was gated using an appropriate isotype control. Mouse TAM panels were as follows. Immunocompetent mouse TAMs: Hoechst − , CD45 + , CD8a − , CD19 − , Ter119 − , TCRβ − , CD11b + and F4/80 + . Immunocompromised mouse TAMs: Hoechst − , CD45 + , Gr1 low or negative , CD11b + and F4/80 + . M1 mouse TAMs: Hoechst − , TCRβ − , CD11b + , F4/80 + , CD206 − and MHC II + . M2 mouse TAMs: Hoechst − , TCRβ − , CD11b + , F4/80 + , CD206 + and MHC II low or negative . Note: TAMs that did not adhere to either of these expression profiles were not classified as M1 or M2. Human samples. The Human Immune Monitoring Center Biobank received IRB approval to obtain patient colorectal cancer samples, and obtained informed consent from all patients.
Cryopreservation of human colorectal cancer samples. The Human Immune
Monitoring Center Biobank carried out colorectal cancer sample preservation as follows. Following a surgical procedure, cancer samples were finely minced with razor blades, then incubated for 15 min at room temperature in PBS containing 6.5 mM dithiothreitol (DTT) to remove mucus. Samples were then washed with Hank's Balanced Salt Solution (HBSS) to remove DTT, and centrifuged at 1,500 r.p.m., for 5 min, at 4 °C. Pellets were then resuspended in RPMI containing 200 U ml −1 collagenase type III (Worthington) and 100 U ml −1 DNase I (Worthington), and incubated at 37 °C for 2 h. The suspensions were mixed by pipetting, and filtered over a 70-μ m filter and then a 40-μ m filter. Samples were spun down, and blood cells lysed with ACK buffer for 5 min at room temperature, then washed with cold PBS and spun down. Samples were subsequently resuspended in 90% FBS and 10% DMSO, aliquoted into cryovials and frozen. FACS of human macrophages. Cryopreserved colorectal cancer samples were thawed rapidly in a 37-°C water bath, washed with PBS, and then spun down for 5 min at 4 °C and 1,200 r.p.m. Cells were blocked with 1 μ g α CD32 per 10 6 cells for 15 min on ice, before being stained with the antibody panel below. Photomultiplier tube (PMT) voltages were set with fully stained samples, and compensations were performed with single-stained UltraComp eBeads (Affymetrix) or cells. For all channels, positive and negative cells were gated on the basis of FMOs, and PD-1 was gated using an appropriate isotype control. Human TAM panels are as follows. M1 human TAMs: Hoechst − , CD45 + , TCRα /β − , CD11b + , CD64 + and CD206 − . M2 human TAMs: Hoechst − , CD45 + , TCRα /β − , CD11b + , CD64 − and CD206 + . Human colorectal cancer staging analysis. Pathology reports for human colorectal cancer patients were obtained and deidentified, according to Stanford IRB protocols. Disease stage was converted to a number scale as shown in Supplementary Table 2 . Stage of disease was plotted on a number scale versus PD-1 expression on human TAMs. Syngeneic tumour models. 6-8-week-old female or male BALB/c mice were shaved on their lower back and engrafted with CT26 colon carcinoma cells by subcutaneously injecting 1 × 10 6 cells in a 100 μ l suspension, consisting of 25% Matrigel Basement Membrane Matrix (Corning) and 75% RPMI (Life Technologies). For the bone marrow transplantation model, 6-week post-transplant C57BL/6 mice were engrafted with MC38 colon carcinoma cells by the same method. Tumours were used for FACS and immunofluorescence microscopy between 13 and 30 days, before reaching 2.5 cm in diameter. Tumours were measured with digital callipers and approximated as ellipsoids with two radii, x and y, where x is the largest measurable dimension of the tumour and y is the dimension immediately perpendicular to x, using the formula: volume = 4/3π × (x/2) 2 × (y/2). Bone marrow transplantation model. 4-6-week-old GFP + C57BL/6 mice were irradiated with 50 rads min −1 before transplantation. Following irradiation, 4-6-week-old RFP + C57BL/6 mice were euthanized and their bone marrow collected from tibia and femurs. In brief, bones were crushed, and bone marrow was resuspended in PBS and passed over a 70-μ m filter. After centrifugation at 1,200 r.p.m., for 5 min, at 4 °C, the blood cells were lysed using ACK lysis buffer for 5 min at room temperature, then spun down again. Following lysis, remaining cells were again passed over a 70-μ m filter, counted, and resuspended at 1 × 10 6 cells per 100 μ l in PBS for transplantation. Irradiated host GFP + mice were transplanted with 1 × 10 6 cells via retro-orbital injection. Six weeks later, host mice were bled to assess donor chimaerism using FACS. Once donor chimaerism was confirmed, mice were engrafted subcutaneously with the MC38 cell line, as described above in (see 'Syngeneic tumour models'). To determine the percentage of TAMs and TILs that were PD-1 + , gating was as follows. PD-1 + donor TAMs: Hoechst − , RFP + , TCRβ − , CD11b + , F4/80 + and PD-1 + . PD-1 + donor TILs: Hoechst − , RFP + , TCRβ + and PD-1 + . PD-1 + host TAMs: Hoechst − , GFP + , TCRβ − , CD11b + , F4/80 + and PD-1 + . PD-1 + host TILs: Hoechst − , GFP + , TCRβ + and PD-1 + . Immunocompromised in vivo phagocytosis analysis. For in vivo phagocytosis analysis, BALB/c Rag2 −/− γc −/− mice were engrafted with either 2.5 × 10 4 CT26-tg(hPD-L1)-Δ (mPD-L1)-YFP-luc + or CT26-Δ (mPD-L1)-YFP-luc + cells by subcutaneously injecting 1 × 10 6 cells in a 100 μ l suspension, consisting of 25% Matrigel Basement Membrane Matrix (Corning) and 75% RPMI (Life Technologies). Any mice with non-engrafting tumours were removed from the study. Tumours were allowed to grow for 21 days, at which point tumour volumes were measured, and outliers in each group were removed using Prism Outlier Calculator (http://graphpad.com/quickcalcs/Grubbs1.cfm). PD-1 − and PD-1 + TAM phagocytosis were determined by FACS, with phagocytosis defined as YFP + TAMs (see Fig. 3b for example gating). Outliers for phagocytosis were removed. Phagocytosis between repeated experiments was normalized by comparing raw phagocytosis values to the maximum phagocytosis in each experimental cohort. Immunocompromised tumour treatment studies. 6-8-week-old male NSG mice were engrafted with 5 × 10 4 DLD-tg(hPD-L1)-GFP-luc + cells. Day 5 after engraftment, tumour total flux (photons s −1 ) was quantified using bioluminescence imaging (BLI). Outliers were removed, and mice were randomized into groups such that each treatment group would have similar average total flux values. Mice were treated intraperitoneally for 21 (HAC versus α PD-1 study) or 28 days (HAC ± α CD47 study). Treatment conditions were PBS (daily), 250 μ g HAC (daily), 250 μ g α PD-1 (clone 29F.1A12, BioXCell; daily) or and 250 μ g α CD47 (clone B6.H12, BioXCell; every other day). BLI measurements or calliper measurements were taken periodically to assess tumour growth. For survival shows that the presence or absence of PD-L1 does not affect PD-1 − TAM phagocytosis. PD-L1 overexpression, n = 7; PD-L1 knockout, n = 9, two experimental repeats. Paired one-tailed t-test. c, TAM PD-1 expression is not affected by the presence or absence of PD-L1. PD-L1 overexpression, n = 7; PD-L1 knockout, n = 9, two experimental repeats. Paired one-tailed t-test. Data are mean ± s.e.m.; n.s., not significant.
